InvestSMART

Orthocell Limited (ASX: OCC) - Announcements

- Current share price for OCC : $0.555

ASX company news and announcements for Orthocell Limited (OCC) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Orthocell Limited (OCC) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Orthocell Limited (OCC), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Orthocell Limited (OCC)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$151 Notification regarding unquoted securities - OCC 26 May 2023 8:27AM $0.345 $0.555 risen by 60.87%
$151 Quarterly Activity Report & Appendix 4C 27 Apr 2023 9:03AM $0.400 $0.555 risen by 38.75%
$151 Cleansing Notice 19 Apr 2023 1:32PM $0.430 $0.555 risen by 29.07%
$151 Application for quotation of securities - OCC 19 Apr 2023 1:22PM $0.430 $0.555 risen by 29.07%
$151 Notification regarding unquoted securities - OCC 19 Apr 2023 1:22PM $0.430 $0.555 risen by 29.07%
$151 Orthocell commences nerve repair study 18 Apr 2023 9:00AM $0.420 $0.555 risen by 32.14%
$151 Leading US-based nerve surgeons appointed to advisory board 29 Mar 2023 9:12AM $0.360 $0.555 risen by 54.17%
$151 Initial Director's Interest Notice-RT 8 Mar 2023 2:13PM $0.390 $0.555 risen by 42.31%
$151 Notification regarding unquoted securities - OCC 8 Mar 2023 2:09PM $0.390 $0.555 risen by 42.31%
$151 Orthocell Appoints Non-Executive Director Dr Ravi Thadhani 8 Mar 2023 9:12AM $0.390 $0.555 risen by 42.31%
$151 Orthocell appoints Company Secretary Mr Peter Webse 1 Mar 2023 9:50AM $0.385 $0.555 risen by 44.16%
$151 Half Yearly Report and Accounts 28 Feb 2023 6:10PM $0.385 $0.555 risen by 44.16%
$151 Investor Presentation 2 Feb 2023 9:56AM $0.395 $0.555 risen by 40.51%
$151 Appendix 4C - Quarterly 30 Jan 2023 1:15PM $0.425 $0.555 risen by 30.59%
$151 Change of Director's Interest Notice PA 23 Nov 2022 9:08AM $0.495 $0.555 risen by 12.12%
$151 Change of Director's Interest Notice LL 23 Nov 2022 9:08AM $0.495 $0.555 risen by 12.12%
$151 Notification of cessation of securities - OCC 23 Nov 2022 9:03AM $0.495 $0.555 risen by 12.12%
$151 Notification of cessation of securities - OCC 23 Nov 2022 9:02AM $0.495 $0.555 risen by 12.12%
$151 Change of Director's Interest Notice LL Revised 11 Nov 2022 10:56AM $0.430 $0.555 risen by 29.07%
$151 Change of Director's Interest Notice LL 9 Nov 2022 9:12AM $0.430 $0.555 risen by 29.07%
$151 Remplir Gains Australian Reimbursement 1 Nov 2022 9:14AM $0.420 $0.555 risen by 32.14%
$151 Appendix 4C - Quarterly 31 Oct 2022 6:24PM $0.420 $0.555 risen by 32.14%
$151 Results of Meeting 28 Oct 2022 2:35PM $0.410 $0.555 risen by 35.37%
$151 Investor Presentation 26 Oct 2022 9:43AM $0.400 $0.555 risen by 38.75%
$151 OrthoATI Rotator Cuff Study Success With Cross-Over Patients 29 Sep 2022 8:38AM $0.405 $0.555 risen by 37.04%

301 - 325 of 777 results

Page 13 of 32

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.